活血化瘀中药联合西医抗血小板药物在冠心病二级预防中的可能优势  

The superiority of combining Chinese medicinals for promoting blood circulation and removing blood stasis with antiplatelet drugs in the secondary prevention of coronary heart disease

作　　者：史大卓[1] SHI Dazhuo(Xiyuan Hospital,China Academy of Chinese Medical Sciences,Beijing 100091,China)

机构地区：[1]中国中医科学院西苑医院,北京100091

出　　处：《北京中医药大学学报》2023年第7期897-901,共5页Journal of Beijing University of Traditional Chinese Medicine

基　　金：国家中医药管理局中医药创新团队及人才支持计划项目(No.ZYYCXTD-C-202007)。

摘　　要：抗血小板药物阿司匹林、氯吡格雷等是冠心病二级预防的基石,可明显改善患者的临床预后,但长期服用可增加出血风险和耐药性。近年来,临床研究显示,活血化瘀中药联合西医抗血小板药物可进一步降低冠心病患者的致残率和死亡率,且不增加出血风险,但证据水平有待进一步提高,以促进临床转化应用。因此,如何根据现代循证医学理念,拓展和深化活血化瘀中药联合西医抗血小板药物治疗冠心病的临床和机理研究,客观评价其疗效和安全性优势,阐释其生物作用机理,对冠心病的二级预防具有重要意义。Antiplatelet drugs such as aspirin and clopidogrel are the cornerstones of the secondary prevention of coronary heart disease(CHD),which can significantly improve treatment outcomes;however,long-term use increases the risk of bleeding and drug resistance.Recent clinical studies have shown that the combination of Chinese medicinals for promoting blood circulation and removing blood stasis with antiplatelet drugs has further reduced the disability rate and mortality of patients with CHD without increasing the risk of bleeding,but the evidence needs to be further strengthened for clinical application.Therefore,to achieve the secondary prevention of CHD,it is important to expand the clinical and mechanistic studies on the prevention and treatment of CHD with Chinese medicinals for promoting blood circulation and removing blood stasis combined with antiplatelet drugs according to the requirements of evidence-based medicine,objectively evaluating its efficacy and safety advantages,and exploring its biological mechanism.

关 键 词：活血化瘀 中药 抗血小板药物 冠心病 二级预防 

分 类 号：R256.22[医药卫生—中医内科学]